ArticleJournal of palliative medicine2017
Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness.
Article in Journal of palliative medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT01415934. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multisite Randomized Controlled Trial of Continuing vs. Discontinuing Statins
Open the trial in the graphWho cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Deprescribing statins for adults 65 years of age and older: Evidence-based clinical practice guideline.Canadian family physician Medecin de famille canadien · 2026Guideline
- Deprescribing decisions in palliative care: a qualitative meta-synthesis of multi-stakeholder experiences and influencing factors.BMC palliative care · 2026Pooled it
- Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review.BMJ open · 2022Pooled it
- Pooled it
- Attitudes Towards Deprescribing Among Older Adults with Limited Life Expectancy and Their Relatives: A Systematic Review.Drugs & aging · 2020Pooled it
- The Statin Paradox: Drivers and Consequences of Therapy Discontinuation.Metabolites · 2026Review
- Trajectories of Medication Use Prior to Death in US Nursing Home Residents With Dementia.Journal of the American Medical Directors Association · 2026Article
- Deprescribing for patients nearing end of life: views, barriers and facilitators of palliative care patients, carers and nurses.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Perceptions of deprescribing for patients with limited life expectancy in primary care.Primary health care research & development · 2025Article
- Medication Prescriptions for Chronic Diseases in Terminal Cancer Patients in Korea: A Real-World Study.Journal of hospice and palliative care · 2025Article
- Older Adult Perspectives on Statin Continuation and Discontinuation in Primary Cardiovascular Disease Prevention: A Mixed-Methods Study.Patient preference and adherence · 2024Article
- DEprescribing: Perceptions of PAtients living with advanced cancer. A multicentre, prospective mixed observational study protocol.PloS one · 2024Article
- Current Landscape and Future Directions of Deprescribing and Polypharmacy Practices in Jordan.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Review
- Perspectives on deprescribing in palliative care.Expert review of clinical pharmacology · 2023Review
- Beliefs and attitudes of residents, family members and healthcare professionals regarding deprescribing in long-term care: a qualitative study.International journal of clinical pharmacy · 2022Article
- Patient and Family Participation in Medication Decisions on Discharge to Hospice Care.Journal of palliative medicine · 2022Article
- Deprescribing in Palliative Cancer Care.Life (Basel, Switzerland) · 2022Review
- Sex-Differences in Discontinuation of Statin Treatment in Cancer Patients the Year before Death.Pharmaceuticals (Basel, Switzerland) · 2021Article
- PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.Archives of medical science : AMS · 2021Article
- Statin Discontinuation and Life-Limiting Illness in Non-Skilled Stay Nursing Homes at Admission.Journal of the American Geriatrics Society · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
backgroundOptimal management of chronic medications for patients with life-limiting illness is uncertain. Medication deprescribing may improve outcomes in this population, but patient concerns regarding deprescribing are unclear.
objectiveThe aim of this study was to quantify the perceived benefits and concerns of statin discontinuation among patients with life-limiting illness.
designBaseline data from a multicenter, pragmatic clinical trial of statin discontinuation were used. SETTING/SUBJECTS: Cognitively intact participants with a life expectancy of 1-12 months receiving statin medications for primary or secondary prevention were enrolled. MEASUREMENTS: Responses to a 9-item questionnaire addressing patient concerns about discontinuing statins were collected. We used Pearson chi-square tests to compare responses by primary life-limiting diagnosis (cancer, cardiovascular disease, other).
resultsOf 297 eligible participants, 58% had cancer, 8% had cardiovascular disease, and 30% other primary diagnoses. Mean (standard deviation) age was 72 (11) years. Fewer than 5% of participants expressed concern that statin deprescribing indicated physician abandonment. About one in five participants reported being told to take statins for the rest of their life (18%) or feeling that discontinuation represented prior wasted effort (18%). Many participants reported benefits of stopping statins, including spending less money on medications (63%), potentially stopping other medications (34%), and having a better quality of life (25%). More participants with cardiovascular disease as a primary diagnosis perceived that quality-of-life benefits related to statin discontinuation (52%) than participants with cancer (27%) or noncardiovascular disease diagnoses (27%) [p = 0.034].
conclusionFew participants expressed concerns about discontinuing statins; many perceived potential benefits. Cardiovascular disease patients perceived greater potential positive impact from statin discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.